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Abstract
Background: Auto-antibodies with specificity to self-antigens have been implicated in a wide variety of neurological
diseases, including Parkinson’s (PD) and Alzheimer’s diseases, being sensitive indicators of neurodegeneration and focus for
disease prevention. Of particular interest are the studies focused on the auto-immune responses to amyloidogenic proteins
associated with diseases and their applications in therapeutic treatments such as vaccination with amyloid antigens and
antibodies in PD, Alzheimer’s disease and potentially other neurodegeneration ailments.
Methodology/Principal Findings: Generated auto-antibodies towards the major amyloidogenic protein involved in PD
Lewy bodies – a-synuclein and its amyloid oligomers and fibrils were measured in the blood sera of early and late PD
patients and controls by using ELISA, Western blot and Biacore surface plasmon resonance. We found significantly higher
antibody levels towards monomeric a-synuclein in the blood sera of PD patients compared to controls, though the
responses decreased with PD progression (P,0.0001). This indicates potential protective role of autoimmunity in
maintaining the body homeostasis and clearing protein species whose disbalance may lead to amyloid assembly. There
were no noticeable immune responses towards amyloid oligomers, but substantially increased levels of IgGs towards a-
synuclein amyloid fibrils both in PD patients and controls, which subsided with the disease progression (P,0.0001). Pooled
IgGs from PD patients and controls interacted also with the amyloid fibrils of Ab (1–40) and hen lysozyme, however the
latter were recognized with lower affinity. This suggests that IgGs bind to the generic amyloid conformational epitope,
displaying higher specificity towards human amyloid species associated with neurodegeneration.
Conclusions/Significance: Our findings may suggest the protective role of autoimmunity in PD and therefore immune
reactions towards PD major amyloid protein – a-synuclein can be of value in the development of treatment and diagnostic
strategies, especially during the early disease stages.
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Introduction
Protein aggregation leading to amyloid deposition in the brain is
implicated in the pathology of a number of neurodegenerative
diseases such as Parkinson’s (PD), Alzheimer’s (AD), prion diseases
and others [1,2,3,4]. The amyloid deposits can be built up from
sequentially and structurally diverse proteins and peptides,
however when they self-assembled into amyloid fibrils, the latter
display a common denominator - a cross-b-sheet core stabilized by
a dense inter- and intra-molecular hydrogen bond network
between the amino and carbonyl groups of polypeptide chain.
Remarkably, the amyloid species display also a generic confor-
mational epitope, reflecting their common architecture, which is
recognized by the oligomer- and fibril-reactive immunoglobulin
antibodies, though the molecular basis of this recognition is still
debated [5,6] The amyloid reactive antibodies, due to their unique
specificity, have significant diagnostic and therapeutic potential for
patients with amyloid-associated diseases. It has been suggested
that autoimmune reactions towards specific proteins and their self-
assembled complexes involved in disease pathology can be used as
sensitive biomarkers of neurodegeneration in both AD and PD
[7,8,9]. Immunoglobulin G (IgG) antibodies that recognize a
conformational epitope(s) of the fibrils of Ab peptide and other
polypeptides, but do not recognize these components in their
native non-fibrillar states, have been found even in healthy human
sera [10]. This suggests that autoimmune reactivity can play an
important role as potential amyloid clearance mechanism in both
health and disease. Recently, the vaccine development has
received great attention among therapeutic approaches in AD
treatment [11,12,13,14]. This includes both passive vaccination
with antibodies [11,12] and active vaccination with Ab42 peptide
[14] and its pre-aggregated forms [13]. The discovery by Schenk
et al. [14], that mice immunized with Ab42 peptide has significantly
reduced amyloid deposits and neuritic pathology, was the most
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showed that it is possible not only to slow the progression of
amyloid deposits, but even reverse them. The active immuniza-
tion, which generates antibodies neutralising amyloid toxicity
[13,15], has opened an avenue to treat AD in humans. However,
the active anti-Ab vaccination trial in patients with mild-to-
moderate AD was prematurely halted when 6% of inoculated
individuals developed aseptic meningoencephalitis [16]. In our
research we examined the autoimmune reactions towards the key
component of PD amyloid deposits – a-synuclein and its
aggregated species and discussed their role in neurodegenerative
processes.
PD is the second most common neurodegenerative disorder
with a prevalence progressively increasing from 0.6 to 3.5% during
aging from 65 to 89 y.o. as shown in collaborative surveys
conducted in France, Italy, Spain and Netherlands [17] as well as
the study performed in the Northern Sweden demonstrated a
cumulative incidence (lifetime risk) being close to 3% among the
population with up to 89 years of age [18]. PD is characterized by
resting tremor, bradykinesia and muscular rigidity. Most of PD
cases (90–95%) are sporadic, whereas familial PD constitutes only
5–10%. Dopamine neurons in the substantia nigra region of PD
brain are characterized by intracellular amyloid deposits of a-
synuclein known as Lewy bodies [19]. PD progression is
commonly associated with death of dopaminergic neurons and
up to 70–80% of neurons in the substantia nigra may be already
dead by the time when the clinical symptoms become obvious
[20].
a-synuclein is relatively abundant in the brain under non-
pathological conditions. It is a natively unfolded protein present
mostly in the cytosol. It plays an essential role in synaptic
transmission and synaptic plasticity by augmenting transmitter
release from the presynaptic terminal [21]. There is substantial
evidence that the conversion of a-synuclein from its soluble into
the aggregated insoluble form is one of key events in the
pathogenesis of PD [22,23]. In vitro a-synuclein can also self-
assemble into ordered amyloid species, which are similar to those
found in Lewy bodies or formed by other amyloid polypeptides,
such as Ab, thus confirming that a-synuclein is naturally
amyloidogenic protein [24]. Lewy bodies grow intracellularly,
but upon the neuronal death or damage of axons in the substantia
nigra, the aggregated species of a-synuclein are released into the
extracellular space [19,23]. Among them, soluble oligomers are
primarily toxic to the cells [25,26,27]. It is important to note, that
recently it has been shown in Saccharomyces cerevisiae [28],
Caenorhabditis elegans [29] and Drosophila melanogaster [30] models
that a-synuclein, if over expressed, itself can be also damaging to
cells, causing oxidative stress, vesicle trafficking defects and
impairment of chaperon and ubiquitin-proteasome systems. Both
monomeric and oligomeric a-synuclein have been found in the
cerebrospinal fluid (CSF) and serum of PD patients
[31,32,33,34,35,36], as apparently a-synuclein and even its
aggregated species can cross the blood brain barrier. In this study
we assessed if the immune reactivity towards a-synuclein
monomeric and amyloid forms in the blood sera can be detected
and possibly serve as a biomarker in PD diagnostics and
prognostics; we set our primary focus on the initial PD stages
when the clinical diagnostics is particularly challenging.
Results
a-synuclein amyloid formation
In order to produce amyloid species, a-synuclein was incubated
at 37uC with continuous agitation (see Materials and Methods).
Aliquots were collected at regular intervals and subjected to
thioflavin T binding assay, assessing the formation of typical
amyloid cross-b-sheet structure, which is manifested in an increase
of fluorescence intensity measured at 485 nm (Figure 1A). The
kinetics of amyloid formation at 0.71 mM concentration of a-
synuclein displayed a sigmoidal shape and the samples containing
mature amyloid fibrils were collected on 10
th day of incubation,
corresponding to the plateau region (Figure 1A). The samples
containing oligomers were collected at the end of the lag-phase of
ca. 6 days, during which we observed small but steady fluorescence
increase upon incubation of the samples with both 0.71 and
0.21 mM protein concentrations. In order to exclude the presence
of some spontaneously formed fibrils in the oligomeric fractions,
the oligomers produced at lower 0.21 mM concentration of
protein were taken for further experiments.
The morphology of aggregated species was examined by AFM
imaging as shown in Figures 1B, 1D. The oligomers significantly
populated in the sample after 6 days of incubation displayed a
round-shaped morphology with the wide distribution of heights
from 1.2 to 2.8 nm and centered at ca. 2 nm as measured in the
AFM cross-sections (Figure 1C); the fibrils have not been observed
in this sample (Figure 1B). After 10 days of incubation we observed
an extensive network of mature amyloid fibrils (Figure 1D),
characterized by significant length of up to 2–5 mm and height in
AFM cross-sections of 8–10 nm, indicative of inter-winding of a
few amyloid protofilaments.
The interaction of amyloid species with generic A11 antibodies
reactive towards the amyloid oligomers were examined by the dot
blot analysis and shown in the top panel in Figure 1C. Indeed, we
observed that A11 antibodies interact with the oligomeric species
populated during days 2 to 6 in the 0.21 mM sample, but the
binding subsides in the aliquots, containing mature fibrils collected
on day 8 and 10 from the 0.71 mM sample, even though the latter
has a higher quantity of amyloids.
The oligomers and fibrils of a-synuclein bind also amyloid
specific dye - Congo red, which is reflected in a long-wavelength
shift and increase of the dye absorbance spectra compared to the
control measurement of Congo red spectrum in the presence of
monomeric a-synuclein (Figure 1E). The Congo red binding to
oligomers caused only ca. 2 nm red shift (the long-wavelength shift
is more obvious in the differential spectrum, i.e. when the
spectrum of Congo red alone is subtracted from the spectrum of
Congo red in the presence of the target oligomers [37], data not
shown) and small increase of the spectrum, while upon interaction
with fibrils the effect was much more pronounced, leading to the
ca. 2 fold increase of absorbance and ca. 30 nm red spectral shift
(Figure 1E). The development of b-sheet core in the amyloid
species were monitored also by the far UV circular dichroism (CD)
spectra (Figure 1F). The monomeric protein possesses a spectrum
typical of a disordered polypeptide chain, characterized by the
presence of the intensive minimum in the 197 nm region. Small
broad shoulder between ca. 215 and 235 nm emerges in the
oligomer-containing sample indicating a slightly more ordered
secondary structure than the natively unfolded monomeric a-
synuclein and very low if any b-sheet content. With this respect,
the spectrum of oligomeric sample resembles those of oligomers
produced at 20 to 100 mM NaCl concentrations and pH 7.5,
37uC, 600 ppm shaking in [38]. By contrast the fibrillar sample of
a-synuclein displays a very characteristic b-sheet spectrum with a
broad band centered at ca. 216 nm.
As cytotoxicity is viewed as the most harmful manifestation of
amyloid assemblies, we examined the effect of a-synuclein amyloid
species on the viability of SH-SY5Y cells (Figure S1). The
oligomers characterized above (Figure 1B) reduced cell viability by
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cells, respectively, while the fibrillar species (Figure 1D) did not
induce noticeable cytotoxicity.
Autoimmune response towards monomeric a-synuclein
The presence of auto-antibodies against a-synuclein monomeric
species in the peripheral blood sera of each individual from the PD
patient and control groups was assessed by ELISA and
immunoblot detection methods. Prior subjecting to the immuno-
logical screening the freshly dissolved a-synuclein was examined
by SDS-PAGE, which shows a single band corresponding to
monomeric protein (Figure S2). By conducting AFM imagining we
also did not observe any larger aggregated species in the samples
with monomeric a-synuclein (data not shown).
The results of ELISA summarized in the box-plots are
presented in Figure 2A; the representative ELISA titration curves
are shown in Figure 3(A). These observations demonstrate that in
healthy individuals the immune responses towards a-synuclein
were at the cut-off level of ELISA, displaying a very narrow
distribution of titers. By contrast, in early PD patients there was a
significant increase of IgG reactivity towards a-synuclein
(P,0.0001), accounting for rise by ca. 8 fold of mean and median
values of titers compared to these values in controls. There was a
wider distribution of responses in this group than in controls with
ca. 70% of patients displaying high immune reactivity towards a-
synuclein. It is important to note that 3 individuals displayed
particularly high responses, with up to ca. 25 fold enhancement in
the IgG - a-synuclein reactivity as estimated by their titers. In the
blood sera of late PD patients there was also an increase of
immune-reactivity towards a-synuclein (P,0.007) compared to
controls, with ca. 6 fold higher mean and ca. 4 fold higher median,
respectively, and with ca. 58% patients displaying high immune
reactivity, but the values of their titers were lower than in the early
PD group.
The analysis of immune-reactivity in the blood sera of patients
and controls by immunoblotting is summarized in the box-plots in
Figure 2B. The samples of freshly dissolved a-synuclein were
subjected to Western blot analysis and subsequently treated with
the blood sera. The representative Western blots are shown in
Figure 2C, indicating the strong interaction of a-synuclein with
Figure 1. Amyloid properties of a-synuclein. (A) Kinetics of amyloid formation monitored by thoflavin T fluorescence at a-synuclein
concentrations of 0.71 mM (black squares and line) and 0.21 mM (red circles and line). (B) AFM images of a-synuclein oligomers. (C) Top: dot blot
analysis of interactions of anti-oligomeric A11 antibodies with the amyloid containing aliquots; days of amyloid incubation are indicated. Bottom: the
distributions of the z-heights of a-synuclein oligomers measured by AFM cross-section analysis. (D) AFM images of a-synuclein fibrils. Scale bars in x,y-
plain equal to 500 nm (B,D). (E) Congo red binding to a-synuclein monomeric, oligomeric and fibrillar species as denoted by corresponding color
coding. (F) CD spectra of monomeric, oligomeric and fibrillar a-synuclein as denoted by corresponding color coding.
doi:10.1371/journal.pone.0018513.g001
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recognition in the blood sera of representative individual from
the control group, strong recognition of a-synuclein by IgGs in the
PD patient serum from the early PD group and weaker binding in
the specimen from the late PD patient. The box-plots demonstrate
the same tendency as the results obtained by using ELISA: early
PD patients were characterized by a significant increase in IgG
reactivity towards a-synuclein compared to controls (P,0.0001)
with ca. 5 and ca. 10 fold increase of mean and median values,
respectively, as estimated by the density of Western blot bands,
and with 63% of individuals exhibiting the high responses. In the
late PD group the immune responses subsided, showing ca. 4 and
6 fold enhancement in mean and median, respectively (P,0.007),
compared to controls and with ca. 58% of patients showing high
level of antibodies. As Western blot method can be more sensitive
than ELISA, enabling to register the presence of up to picomolar
concentration of antibodies, we have observed some weak
responses towards a-synuclein in 4 individuals in the control
group, which is reflected in a wider distribution of readings in the
corresponding box-plot compared to the ELISA data (Figure 2B).
There were no significant correlations between the immune
responses in PD patients and controls with their age or gender as
assessed by both ELISA and Western blot analyses.
The diagnostic potentials of the ELISA and Western blot
measurements in discriminating the higher autoimmune responses
in early / late PD patients compared to controls were also assessed
statistically by the receiver operating characteristic (ROC) analysis
as shown in Figure 4. The areas under the ROC curves (AUC) for
the autoimmune reactivity determined by ELISA in early and late
PD patients compared to controls were 0.884 (95% confidence
interval of 0.79 to 0.97) and 0.779 (0.6–0.95), respectively. The
AUC values calculated from the corresponding ROC curves for
the Western blot data were 0.85 (0.74–0.95) for early PD vs
controls and 0.817 (0.67–0.95) for late PD vs controls, respectively.
This indicates that the autoimmune responses to a-synuclein have
a high diagnostic value both in early and late PD patients. For the
autoimmune responses determined by ELISA in early PD cases vs
controls, the optimal cut-off value was set at .480 (J=0.59). At
this division, 59% of the early PD cases were true positives with
0% false positives. For the Western blot data the corresponding
Figure 2. Immune responses towards a-synuclein monomer in the blood sera of controls, early and late PD patients. Box-plots
showing statistical distributions of immune responses to a-synuclein measured by ELISA (A) and Western blotting (B). The antibody titers (A) and
Western blot band densities (B) are shown along y-axis and the groups subjected to analysis - along x-axis. Boxes include from 25% to 75% of all
immune responses; central squares indicate the mean and line drawn crossed the box – the median values for each group; whiskers indicate the
distribution from 5% to 95%, while small crosses correspond to remaining 10%. (C) Representative Western blots showing interactions with
monomeric a-synuclein of monoclonal antibodies (mAbs) and sera IgGs from selected control (1), early PD (2) and late PD (3) individuals. (D) Biacore
analysis of the interactions with a-synuclein of pooled IgGs from controls, early and late PD patients. Surface plasmon resonance responses in relative
units are shown in y-axis. ***P,0.0001, **P,0.007 and *P,0.05.
doi:10.1371/journal.pone.0018513.g002
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early PD group with 4% (1 of 23 controls) false positives. For the
immune reactivity in late PD patients vs. controls assessed by
ELISA and Western blot, the optimal cut-off values were .280
(J=0.49) and .45 (J=0.49), respectively, indentifying 58% true
positives and 8.7% (2 of 23 cases) false positives in both
experimental set ups. The AUC for the immune reactivity towards
a-synuclein in early vs late PD patients evaluated by both ELISA
and Western blot analysis were not significantly greater than 0.5
and the ROC curves were close to diagonals, respectively (data not
shown).
To provide an additional support to our findings we have
subjected the pooled purified IgGs from blood sera of controls,
early and late PD patients to Biacore surface plasmon resonance
analysis, by using the Biacore chips coated with a-synuclein
monomers (Figure 2D); the Biacore sensograms are presented in
Figure 3(B). Polyclonal antibody responses are given in relative
units measured after washing, when the signal reached an
equilibrium value, to ensure that only strong binding of a-
synuclein-specific antibodies is registered vs. non-specific interac-
tions with the Biacore chip by other pooled sera IgGs. Consistently
with the ELISA and immunoblot data, the level of IgG binding to
a-synuclein was significantly higher both in the blood sera of early
(P,0.0001) and late (P,0.05) PD patients compared to controls,
however, the late PD group showed decreased level of antibodies
compared to early PD patients.
Autoimmune responses towards a-synuclein amyloid
oligomers and fibrils
The blood sera from PD patients and healthy controls were also
examined on the presence of immune responses towards a-
synuclein oligomers and fibrils. We have not observed any specific
responses towards amyloid oligomers characterized above, neither
in majority of early and later PD patients nor in controls, by using
ELISA (data not shown). There were 2 exceptions in the control
group characterized by the significant titers of IgGs towards
oligomers of ca. 2500 and 650; among 27 early PD patients only 1
individual showed response with ca. 2500 and 2 - with ca. 650
titers, respectively, and in the late PD group 2 patients out of 12
exhibited titers of ca. 650. Examination of the pooled sera from
early and late PD patients and controls by Western blot analysis
did not show substantial immune reactivity (data not shown),
confirming the ELISA results on the lack of immune responses
towards oligomers in the vast majority of healthy and PD
individuals. In control experiments we examined the interactions
of the pooled sera IgGs of PD patients and healthy individuals with
the oligomers of a-synuclein (0.21 mM sample) produced during
six days of incubation at five pH values in the range from 6 to 8
Figure 3. Interaction of a-synuclein species with the sera antibodies of PD patients and controls. ELISA titration curves corresponding to
the interactions of monomeric a-synuclein with IgGs from the blood sera of representative control, early PD and late PD individuals as denoted in the
caption (A). Biacore sensorgrams reflecting the biding of a-synuclein monomer (B) and fibrils (C) with IgGs from the pooled sera of control, young
control (C), early PD and late PD individuals as denoted in the captions.
doi:10.1371/journal.pone.0018513.g003
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conformational properties of oligomers, this enabled us to assess a
wider variety of these potentially heterogeneous species. We did
not observe significant interactions between the oligomeric
samples and pooled IgGs in either of these cases (data not shown).
In order to measure the immune reactivity of sera IgGs towards
amyloid fibrils we used Western blot analysis (Figure 5A,B). The
amyloids were loaded on the native gel; the higher molecular
weight species remained on the top of the gel (representative band
is shown in Figure 5B, left) and, thus, were separated from the
remaining low molecular weight and monomeric a-synuclein
species entering the gel. Consequently, Western blot analysis was
carried out with these species. The Western blots presented in
Figure 5B demonstrate the clear recognition of amyloid fibrils by
specific anti-fibrillar IgGs [6] selected as a reference (band 2) and
by the sera IgGs of representative individuals from the control,
early and late PD groups (bands 3–5), respectively.
The summary of Western blot analysis is presented in the box-
plots in Figure 5A for each examined group, demonstrating
substantial immune responses towards a-synuclein amyloid fibrils
in all of them. There were no statistically significant differences in
the distributions of immune reactivities between the groups with
the mean and median values equal to 117/137, 112/122 and 93/
97 for control, early PD and late PD groups, respectively. Both PD
groups showed the wider distributions of responses than the
control group. In the control group 4 out of 23 individuals were
characterized by rather low anti-fibrillar IgG reactivity. The ROC
analysis of the immune responses to fibrils in early / late PD
patients vs controls gave the AUC values not greater than 0.5 and
ROC curves close to diagonals (data not shown). There were no
significant correlations between the immune responses towards
amyloid fibrils in PD patients and controls with their age or
gender.
The amyloid fibrils of a-synuclein were used also as antigens in
the Biacore experiments, in which they were placed on the Biacore
chip and their interactions with the IgGs purified from the pooled
blood sera of each studied group were monitored as described in
Material and Methods. There was significant immune reactivity
towards fibrillar antigens in all samples with a slight decrease by
ca. 10% between the control and early / late PD groups,
respectively (Figure 5C) (P,0.0001); the Biacore sensograms are
presented in Figure 3(C). This is consistent with the trend of
decreasing immune reactivity towards amyloid fibrils with
progression of PD detected by the Western blot analysis.
Cross-reactivity of anti-fibrillar IgGs with amyloid fibrils of
different protein origin
It has been shown recently that fibril specific, conformation-
dependent antibodies are able to recognize a generic epitope
common to various amyloid fibrils [6] as well as the fibril-reactive
purified antibodies immunostained amyloid deposits in human
tissues and displayed in vivo reactivity in a murine model [10].
Figure 4. Assessment of diagnostic value of autoimmune responses to a-synuclein in PD patients. Receiver operating characteristic
(ROC) curves comparing the autoimmune responses towards a-synuclein between early PD (true positives) and controls (true negatives) determined
by ELISA (A); between late PD and controls determined by ELISA (B); between early PD and controls determined by Western blot (C) and between late
PD and controls determined by Western blot (D). The dotted line indicates the results when the parameter in question has no diagnostic value
(AUC=0.5). The optimum cutoff values (Youden index) are shown by the open circles. The tables summarize AUC, 95% confidence interval (CI), P
value, number of controls and patients.
doi:10.1371/journal.pone.0018513.g004
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patients and controls possess a similar cross-reactivity towards
different fibrillar species and belong to this class of generic fibril
specific antibodies.
Purified IgGs from the pooled blood sera of PD patients and
controls were compared with regards to their reactivity towards
fibrillar antigens of different protein origin, i.e. formed from a-
synuclein, Ab (1–40) peptide and hen egg white lysozyme
(Figure 6A), by using dot blot analysis. Both Ab (1–40) peptide
and hen egg white lysozyme developed mature amyloid fibrils as
described in Material and Methods and examined by AFM
imaging (Figure 6B and 6C). Specific anti-fibrillar IgGs [6], used
as a reference, recognized all types of selected fibrils (Figure 6A,
right), but not corresponding monomers (Figure 6A, left). By
contrast the pooled IgGs of all PD patients and controls,
respectively, interacted with the fibrillar antigens of all selected
polypeptides, though their reactivity with a-synuclein and Ab
peptide fibrils was much more pronounced than with the fibrils of
hen egg white lysozyme. Consistently with the above reported
results, the pooled IgGs of all PD patients and to a lesser extent
IgGs of controls recognized monomeric a-synuclein, but not the
monomers of Ab peptide or hen egg white lysozyme (Figure 6A,
left). This indicates that in blood sera of both PD patients and
controls there are polyclonal IgGs reactive with conformational
epitope of amyloid fibrils, targeting, however, primarily the fibrils
associated with human neurodegenerative ailments (a-synuclein
and Ab peptide).
Discussion
Auto-antibodies with specificity to self-antigens have been
implicated in a wide variety of neurological diseases [7,8,39]
including PD [9,40], as they reflect the pathological changes
occurring in the brain during neurodegeneration. By using a range
of detection methods such as ELISA, Western blot and surface
plasmon resonance by Biacore, we have shown that there is a
substantial increase of immune responses to monomeric a-
synuclein in early PD patients compared to controls, with 70%
of individuals displaying high level of IgGs as estimated by ELISA
and 63% - by Western blot analysis, respectively (Figure 2). The
immune reactivity to a-synuclein decreased in late PD, which
reflected in a lower number of patients exhibiting high immune
responses, i.e. 58% as determined by both ELISA and Western
blot, and also in the lower values of the responses. In both ELISA
and Western blot screening we observed the robust ROC curves
and AUC$ca. 0.8, indicating that the autoimmune reactivity
towards a-synuclein has a significant diagnostic value. Although
the choice of cut-off values is dependent upon the importance of
missing true positives vs. misdiagnosing false positives, the Youden
index values calculated from the ROC curves would suggest that
.480 and .52 cut-offs identify 59% true positives with a 0 and
4% (1 of 23 cases) false positive rate in early PD by using ELISA
and Western blot, respectively, and the cut-offs of .280 and .45
for ELISA and Western blot analysis, respectively, identify 58%
true positives vs. 8.7% (2 of 23 cases) false positives in late PD by
both experimental approaches. No correlation with age or gender
was found.
In previous study by Papachroni et al. [40] the enhanced level of
multi-epitopic antibodies against a-synuclein was also detected in
the blood sera of 65% of PD patients compared to controls by
using Western blot analysis. However, the authors observed
correlation primarily with familial PD, i.e. 90% of patients were
positive for antibodies towards a-synuclein in familial PD vs 48%
in sporadic cases. It is important to note, that these patients were
characterized by ca. 2.5 of Hoehn and Yahr score, which
corresponds to our late PD group, and consistent with lesser
Figure 5. Immune responses towards amyloid fibrils of a-synuclein in the blood sera of controls, early and late PD patients. (A) Box-
plots showing statistical distributions of immune responses measured by Western blotting. The descriptions of box-plots are the same as in Figure 2B.
(B) Representative native gel band corresponding to amyloid fibrils (1) and Western blots bands showing interactions of a-synuclein fibrils with anti-
fibrillar antibodies (2), with sera IgGs from selected control (3) as well as early PD (4) and late PD (5) individuals. (C) Biacore analysis of the interactions
with amyloid fibrils of pooled IgGs from the blood sera of controls, early and late PD patients. Surface plasmon resonance responses in relative units
are shown in y-axis. ***P,0.0001.
doi:10.1371/journal.pone.0018513.g005
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to early PD in our studies.
There is evidence that PD pathology engages humoral
immunity, which is reflected in a detectable level of IgGs in PD
brains, binding to dopaminergic neurons in a concentrated
distribution at neuronal surfaces or co-localized with a-synuclein
on Lewy bodies [41]. Moreover, initiation of humoral immunity in
early onset PD may also be concomitant with inflammation [42],
which plays a role in neurodegenerative diseases [43]. The major
participant of PD - a-synuclein is an abundant neuronal protein
expressed in many neurons, including dopaminergic neurons in
the substantia nigra. Its fibrillar form is a main constituent of the
Lewy bodies. The death of neurons or damage of axons and
synaptic terminals could result in the release of soluble and
aggregated forms of a-synuclein into the extracellular space. There
is also evidence of physiological secretion of a-synuclein into
extracellular environment [44]. Altered a-synuclein metabolism in
the central nervous system can be manifested in the body fluids
and as a result a-synuclein has been found in the CSF and plasma
of PD patients [31,33,35,36,45]. It is interesting to note, that the
decreased level of a-synuclein in CSF was found in the large scale
screening of PD patients compared to AD patients and controls by
Hong et al. [45] as well as an inverse correlation of a-synuclein
content with Hoehn and Yahr score was observed by Tokuda et al.
[32]. However, the results on a-synuclein content in plasma/sera
are highly variable - Li et al. [36] presented a decreased plasma
level of a-synuclein in PD compared to controls as measured by
Western blotting, while Lee et al. [33] reported an increased
plasma a-synuclein concentration in PD compared to controls by
using ELISA. The variations can be related to the fact that cross-
reactive species may involve both monomeric a-synuclein and its
aggregated forms in these measurements.
In PD pathology the autoimmune reactivity can serve as a
protective mechanism aimed to maintain the body homeostasis and
eliminate intrinsic factors leading to its disbalance. As enhanced
concentration of a-synuclein can be a significant aggregation prone
factor, promoting its self-assembly into toxic amyloid oligomeric
species and amyloid fibrils, the autoimmunity can have a potential
protective power, reducing its concentration in the body fluids.
Indeed, vaccination of transgenic mice with human a-synuclein led
to production of highly reactive antibodies, which decreased
accumulation of aggregated a-synuclein in neuronal cell bodies
and synapses and consequently reduced neurodegeneration [46].
Furthermore, antibodies produced by immunized mice recognized
abnormal a-synuclein associated with membrane and promoted the
degradation of its aggregates. Similar effects were observed with an
exogenously applieda-synucleinantibodies,indicatingthatthey can
be a powerful tool in reducing neuronal accumulation of a-
synuclein aggregates [46]. In our studies the increased level of a-
synuclein reactive IgGs found in early PD can fulfill the protective
function reducing the concentration of a-synuclein in the blood
sera. In the late PD group the level of anti-a-synuclein antibodies
and their clearance power subsided, as disbalance in the body
homeostasis can be overwhelming.
Figure 6. Immune reactivity of pooled IgGs from the blood sera of controls and PD patients towards monomers and amyloid fibrils
of different polypeptides measured by dot blot analysis. (A) Dot blots demonstrating the immune reactivity towards monomers of a-
synuclein (AS-M), Ab peptide (Ab-M) and hen egg white lysozyme (HEWL-M) are shown in the left panel and towards corresponding fibrils (AS-F, Ab-F
and HEWL-F) – in the right. The rows of dot blots from top to bottom show the interactions of antigens with added anti-fibrillar antibodies [6] and
pooled IgGs from the sera of controls and all PD patients, respectively. AFM images of amyloid fibrils of Ab peptide (B) and hen egg white lysozyme
(C) subjected to dot blot analysis. Scale bars in x,y-plain equal to 500 nm.
doi:10.1371/journal.pone.0018513.g006
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towards oligomeric species in all studied groups, including
controls, early and late PD patients. By contrast, we have observed
substantial immune responses towards mature amyloid fibrils in
the control group and subsiding, but still pronounced, reactivity in
early PD and to a lesser extend in late PD as measured by Western
blotting (Figure 5A). The consistent decrease of immune reactivity
towards fibrils was detected by Biacore analysis in the pooled
fractions of IgGs of the control, early and late PD groups,
respectively (Figure 5C). The overall decreased reactivity of
naturally occurring antibodies towards monomeric and fibrillar
a-synuclein in late PD patients may be related to T-cell tolerance,
when these cells become deficient in producing antibodies and
providing help in clearance of these molecular species [47].
It is important to note, that amyloid-reactive IgGs are naturally
presentinthe bloodseraofhealthyindividuals,recognizingcommon
conformational epitope of amyloid fibrils regardless of their protein
composition [10,48]. Consistently with this,we have found the cross-
reactivity of IgGs pooled from the blood sera of PD patients and
controls towards the amyloid fibrils of different protein origin
(Figure 6A). Indeed, the pooled IgGs from both groups recognized
the amyloid fibrils of a-synuclein, Ab (1–40) peptide and even to a
smaller extent hen egg white lysozyme fibrils as demonstrated by dot
blot analysis. All types of fibrils exhibited rather similar morphology
as shown by AFM imaging (Figure 1D, 6B, 6C), nonetheless they
may have some sequence or species specificity, which led to
decreased binding of IgGs to hen egg white lysozyme fibrils.
The fact that we did not observe statistically significant immune
reactivity towards the oligomeric species of a-synuclein both in PD
patients and controls, which are the most pathogenic compounds
causing neuronal cell death (Figure S1), maybe related to the fact
that they present transiently and rapidly inter-convert into larger
pre-fibrillar or fibrillar species. Soluble oligomers are often
transient, since they are consumed as fibrillization proceeds
[25,38,49,50]. In situ AFM analysis demonstrated that the
assembly of globular oligomers precedes the formation of amyloid
fibrils and is systematically observed under conditions for
accelerated fibrillation, indicating that the oligomers can act as
on-pathway intermediates during amyloidogenesis [50]. It is
interesting to note, that 5 PD patients and 2 controls exhibited
the significant immune responses towards the oligomeric struc-
tures, which suggests that the latter may be populated in the sera of
some individuals. Furthermore, in our pilot experiment we
observed the immune reactivity towards amyloid fibrils in the
pooled blood sera of 7 young controls of 20–25 years of age
(Figure 3(C)), though at significantly lower level than in older
controls and PD patients. As the presence of amyloid deposits in
healthy individuals of this age group is highly unlikely, it cannot be
ruled out that the amyloids can be formed transiently and the
autoimmunity plays protective role as a natural clearance
mechanism. The normal aging, however, may greatly increase
the chances of protein misfolding and amyloid assembly, which
puts a higher pressure on the clearance system and correlates with
an enhanced level of autoimmune responses to a-synuclein
amyloid fibrils even in the normal aging as well as during disease
development (Figures 5, 3(C)).
As amyloid structures exhibit an inherent heterogeneity and
mutual inter-conversion, we conducted our research on freshly
prepared protein amyloid samples characterized by AFM, the
thioflavin-T and Congo red biding, CD, as well as WST1
cytotoxicity assays (Figure 1, S1). Within our experimental set-up
the amyloid oligomers were characterized by round-shape
structure, weak binding of amyloid-specific dyes such as Congo
red and thioflavin-T, lack of characteristic b-sheet spectrum in the
far UV CD, though they interacted specifically with generic anti-
oligomeric A11 antibodies and displayed pronounced cytotoxicity.
In the previous study by using ELISA method El-Agnat et al.
reported the presence of ‘‘soluble aggregates’’ or oligomers of a-
synuclein in the plasma of PD patients [31]. As there are no
further characteristics of these aggregates apart from their
separation by size exclusion chromatography, it cannot be
excluded that the oligomers subjected as antigens in our analysis
(Figure 1B) and the ‘‘soluble aggregates’’ reported in [31] may
belong to different types of pre-fibrillar or even fibrillar structures
and possess different epitopes.
It is important to note that in the blood sera of PD patients the
immune reactivity towards amyloid oligomers and fibrils of insulin
also was not detected in the previous studies, though there were
elevated autoimmune reactions to both insulin and S100B -
endocrine and astrocytical biomarkers, respectively [9]. By
contrast, in AD patients a significantly increased level of serum
antibodies to both prefibrillar amyloids of Ab and human
lysozyme was found in the early stage of disease [8] and biphasic
antibody levels to Ab peptide oligomers - during the progression of
dementia [7]. The autoimmune responses to Ab oligomers
reflected mild to moderate phases of AD dementia, while those
to S100B protein closely matched moderate to severe dementia
[7]. This suggests that the autoimmune reactivity and neurode-
generation in PD and AD may involve different underlying
mechanisms.
The trends of the autoimmune reactivity towards a-synuclein
and its amyloids fibrils in the blood sera during progression of PD
are summarized in Figure 7. Our findings indicate that the
autoimmune response to a-synuclein can serve as a valid
biomarker, reflecting the progressive brain neurodegeneration
and impaired a-synuclein homeostasis occurring in PD. These
findings, together with assessment of other biomarkers such as the
autoimmune responses to insulin and S100B [9], may complement
clinical investigations and be of importance as an aid for improved
diagnostic accuracy of PD and as a tool to assess evolution of the
disease as well as effects of interventions.
Materials and Methods
Ethics statement
All participants in this research gave informed and written
consent. The study obtained ethics approval by the Umea ˚ medical
ethics committee of the Umea ˚ University and Hospital.
Human subjects
39 PD patients (24 males and 15 females) with a mean age of
63.3 years were recruited from the outpatient clinic of the
Department of Neurology at Umea ˚ University Hospital. The
characteristics of the participants are presented in Table 1.
Patients have been neurologically examined at the Department on
several occasions and diagnosed as having clinically definite PD
according to the UK Parkinson’s Disease Society Brain Bank
clinical diagnostic criteria [51]. Severity was assessed by the
Hoehn and Yahr score [52] and the patients were divided into 2
groups according to the severity of disease: 27 patients were in a
less advanced stage with 1 to 2 score (early PD) and 12 patients in
a more advanced stage of 2.5–4 score according to Hoehn and
Yahr scale (late PD). In 56% (22/39) of the patients the function of
presynaptic dopamine system was investigated by FP-CIT SPECT
imaging. All 22 patients showed reduced uptake of ligand in the
putamen, as expected in PD and other forms of idiopathic
parkinsonism. 2 patients were operated with deep brain stimula-
tion (DBS) for treatment of their PD 5 and 8 years prior to the
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movement disorders, mainly tremor. It was not possible to
examine their relatives for a more exact diagnosis. 3 patients
were treated for high blood pressure and another 3 patients had
diabetes type 2. Patients with concomitant neurological or
psychiatric diseases, cancer and other severe diseases were
excluded. 23 healthy controls, biologically unrelated to the patients
and of similar age and sex distribution as these, were selected from
spouses of patients attending the outpatient clinic. The exclusion
criteria for controls were identical to that of patients.
a-synuclein production
The Escherichia coli BL21 (DE3) cells transformed with
pRK173 plasmid harbouring the a-synuclein gene were used
for the production of the recombinant protein [53]. The
recombinant protein was purified as previously described [54]
with some modifications outlined below. Plated cultures were
used to inoculate Nutrient Broth medium (Oxoid Ltd, UK)
containing ampicillin. Cultures were grown until late log-phase
(A600 nm,0 . 8 )a t3 0 uC and the protein expression was induced
with 0.5 mM isopropyl-b-D-thiogalactopyranoside. The cells
were cultured at 30uC overnight, harvested by centrifugation
(3000 g, 20 min), washed, re-suspended in 50 mM Tris-HCl
buffer, pH 7.5, containing 0.1 mM EDTA, 0.2 mM PMSF and
disrupted by sonication. The cell homogenate was boiled for
10 min, the cell-free extract was loaded onto a HiPrep
TM QF F
16/10 Column (GE Healthcare) in 20 mM Tris-HCl, pH 7.5,
and eluted by a linear 0–1 M NaCl gradient. Fractions
containing a-synuclein were analyzed by a Coomassie stained
SDS-PAGE and dialized against 20 mM Tris, pH 7.5. Collected
fractions were loaded onto a HiTrap ANX FF (high sub) column
and eluted by a linear 0–1 M NaCl gradient. Fractions
containing a-synuclein were combined, dialized against 10 mM
NH4HCO3 and lyophilized.
Figure 7. Schematic presentation of changes in the immune reactivity towards a-synuclein and its amyloids in the blood sera of PD
patients and controls (C). The thickness of the bars and gradients is proportional to immune responses.
doi:10.1371/journal.pone.0018513.g007
Table 1. Group characteristics of PD patients and controls.
PD patients (n=27)
Hoehn/Yahr 1–2
PD patients (n=12)
Hoehn/Yahr 2.5–4
PD patients (n=39)
Total
Controls
(n=23)
Gender male/female 17/10 7/5 24/15 16/7
Age at PD onset 53.9610.1 59.569.5 55.7610.2
Age at blood sample 60.6610.9 69.567.0 63.3610.6 57.4613.8
Duration of PD 6.765.3 9.965.8 7.765.6
UPDRS
| – motor scale 22.2612.4 36.4613.7 25.9614.0
| –UPDRS – Unified Parkinson’s Disease Rating Scale.
doi:10.1371/journal.pone.0018513.t001
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a-synuclein concentration was determined by optical absor-
bance measurements at 280 nm (ND-1000 spectrophotometer,
Nano-drop, Sweden), using an extinction coefficient E1 mg/ml
=0.354 [55]. In order to produce amyloid oligomers and fibrils of
a-synuclein, protein was incubated at 0.21 mM and 0.71 mM
concentrations, respectively, in 10 mM sodium phosphate buffer,
pH 7.4 and 37uC, using continuous agitation at 300 rpm. Amyloid
fibrils of Ab (1–40) peptide were produced in 10 mM NaOH,
pH 7.5 and room temperature after 3 days of incubation by using
protocols described previously [56], while the fibrils of hen egg
white lysozyme were formed in 20 mM glycine buffer at pH 2.2
and 57uC after 14 days of incubation [57,58].
Spectroscopic amyloid assays
Thioflavin T (ThT) binding assay was performed by using the
modification of LeVine’s method [59]. Thioflavin T fluorescence
was measured by a Jasco FP-6500 spectrofluorometer (Jasco,
Japan), using excitation at 440 nm and collecting emission
between 450–550 nm, with excitation and emission slits set at
3 nm width. Congo red assay was performed as described in [57]
by using a ND-1000 spectrophotometer for optical absorbance
measurements. CD measurements were performed by using a
Jasco J-810 spectropolarimeter (Jasco, Tokyo, Japan) equipped
with a Jasco CDF-426L thermostat, using 0.1- and 0.5-cm path
length cuvettes. At least three scans were averaged for each
spectrum.
Atomic force microscopy (AFM)
AFM measurements were performed on a PICO PLUS
microscope (Agilent, USA) in a tapping mode as outlined
previously [37,60]. A scanner with a 100 mm scan size and
acoustically driven cantilevers carrying etched silicon probes of the
TESP model of 10 nm diameter (Veeco, Netherlands) were used.
Typically we applied a resonance frequency in the 312–340 kHz
range, scan rate of 1 Hz and a resolution of 5126512 pixels.
Height, amplitude and phase data were collected simultaneously.
Images were flattened and plane adjusted. The scanning of
samples was performed in trace and retrace to avoid the scan
artifacts. The scanner was calibrated by measuring atomic steps on
highly orientated pyrolytic graphite in the z-axis and using a
standard 1-mm calibration grid (Agilent, USA) in the xy-plane.
Amyloid samples were deposited on the surface of freshly cleaved
mica (GoodFellow, UK) for 30 min, washed three times with
100 ml of MilliQ water, and dried at room temperature. To
determine the dimensions of amyloid species cross-section analysis
in the height images was carried out using PICO PLUS software
(Agilent, USA).
Enzyme linked immunosorbent assay (ELISA)
The titers of serum antibodies to a-synuclein monomers and
oligomers were determined by ELISA in 96-well polystyrol plates
(Costar, USA) using 6 repetitions per sample. Microtiter wells
were coated with the a-synuclein antigens at concentrations of
15.0 and 20.0 mg/ml of monomers and oligomers, respectively, in
50 mM phosphate buffer, pH 8.0 (4uC) and assayed by the
protocol described in [8,9]. The titer of each serum sample was
derived from the reciprocal of the largest dilution at which the
enzyme-substrate reaction gave an optical density value greater
than that of the mean optical density of blanks (0.1 optical
density). The values of titers at which we observed immunore-
activity to the antigens were represented in relative dilution ratio
units.
Electrophoresis and immunoblotting
Gel electrophoresis was performed under reducing conditions
by using 15% SDS-PAGE gels to analyze the samples of freshly
dissolved a-synuclein. Protein solutions were mixed with SDS
loading buffer prior applying to SDS-PAGE. Larger molecular
weight species such as a-synuclein amyloid oligomers and fibrils
were separated by using native 8–25% gradient gels (Phast gels,
GE Healthcare, Sweden). Coomassie brilliant blue R250 (Sigma,
USA) was used for gel staining. Pre-stained molecular weight
standards ‘‘SeeBlue’’ (Invitrogen, USA) were included in each
experiment.
Immunoblotting was performed by using nitrocellulose mem-
branes (0.45 mm, GE Healthcare, Sweden). Samples of monomer-
ic a-synuclein and its amyloid species were transferred to
membranes at 200 mA during 3 h and blocked with 5% milk in
Tris buffered saline (TBS) containing 0.1% of Tween 20. Immune-
reactivities between monoclonal antibodies towards a-synuclein
(Abcam, UK), polyclonal antibodies towards amyloid oligomers
and fibrils [5,6] and respective antigens were used as positive
controls in each experiment. Blood sera samples from PD patients
and controls were applied to identify primary IgG interactions
with a-synuclein antigens. Peroxidase-conjugated anti-human
IgGs were used as secondary antibodies and their immune-
reactivity was detected by using the enhanced chemiluminescence
method (GE Healthcare, Sweden). Dot blot experiments were
performed following the same procedure; we used 1 to 3 mgo f
freshly dissolved monomeric proteins and 3 to 4 mg of fibrillar
materials per dot blot. The immune responses observed in the
immunoblot analysis for individual PD patients and healthy
controls were quantified densitometrically by using a Scion image
software (NIH). Anti-oligomeric A11 [5] and anti-fibirllar [6]
antibodies were a gift from Rakez Kayed.
IgG Purification
Total IgG fraction from the blood sera was purified by using a
Melon Gel Purification kit (Pierce Biotechnology, USA) according
to the manufacturer’s protocol. Purity of the IgG antibodies was
assessed by 15% SDS PAGE.
Biacore
The interaction between purified pools of IgGs from the blood
sera and a-synuclein antigens were examined by a Biacore 3000
surface plasmon resonance instrument equipped with a CM4
sensor chip (GE Healthcare, Sweden). Monomers, oligomers and
fibrils of a-synuclein were covalently immobilized in the flow cell
with a target level of 10,000 RUs at 0.1 mg/ml concentration in
10 mM sodium acetate, pH 3.0, at room temperature. Total
pooled IgGs were injected at 0.5 mg/ml concentration in filtered,
degassed 0.01 M HEPES buffer, 0.15 M NaCl, 0.005% surfactant
P20, pH 7.4 (GE Healthcare, Sweden) at a flow rate of 10 ml/min.
The signal at the equilibrium level of the dissociation curve was
taken as the measure of antigen-antibody interactions to exclude
the non-specific interactions of all pooled IgGs with the Biacore
chip [61].
WST-1 cell viability assay
The neuroblastoma cell line SH-SY5Y [62] was used as in the
previous studies Gharibyan et al. [58] and was originally purchased
(Sigma, USA). This cell line were cultured in a Dulbecco’s
modified Eagle’s medium supplemented with 10% (v/v) fetal
bovine serum and antibiotics in a 5% CO2 humidified atmosphere
at 37uC. Cells were plated at a density of 10
4 cells/well in 96-well
plates, incubated for 24 hours, and then the medium was changed
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synuclein samples were initially diluted in the culture medium
and then added to the cells to achieve final concentration of
50 mM as described previously [58,60]. Untreated cells as well as
cells treated with the amyloid incubation buffer (10 mM sodium
phosphate, pH 7.4) were used as controls.
In order to evaluate cell viability, 10 ml of water-soluble
tetrazolium salt (WST-1) reagent was added per 100 ml of cell
culture and samples were incubated at 37uC for 4 hours.
Absorbance was measured with an ELISA plate reader (Tecan,
Sweden) at 450 nm. Cell viability was expressed as a percentage of
the absorbance in the wells containing cells treated with amyloid
compared to the control wells. The experiments were performed
in triplicate in each series and the results were presented as
mean6SEM.
ROC analysis
ROC analysis was used to quantify the potency of the ELISA
and Western blot screening to discriminate between the
autoimmune responses to a-synuclein in PD patients and controls.
The ROC curves were plotted as the number of true-positives
(sensitivity) vs. the number of false-positives (1-specificity) for all
possible cut-off values. The areas under ROC curves (AUC) were
calculated to evaluate the diagnostic values of the marker. If the
test is without diagnostic power, the ROC curve will be linear with
AUC of 0.5, (shown by dotted line in Figure 4). A perfect test
would give an AUC of 1.0, indicating that it has zero false positives
and zero false negatives. The higher AUC above 0.5, the better the
test. For AUC.0.5, the choice of cut-off is a trade-off between the
risk of missing true positives and of selecting false positives. Here
we used approach based on the Youden index, J, calculated as
maximum sensitivity + specificity 21. J corresponds to the
maximum vertical distance between the ROC curve and the
diagonal or chance line and it occurs at the cut-off point when
equal weight is given to sensitivity and specificity [63,64].
Statistical calculations were performed using the statistical package
built into the GraphPad Prism 5 computer programme for the
Macintosh (GraphPad Software Inc., San Diego, CA,USA).
Statistical analysis
Statistical significance of measurements was assessed by using a
non-parametric Mann Whitney U test and by a two-tailed Student
t-test. The level of significance was set at P,0.05 (***=P,0.0001,
**=P,0.007, * P,0.05).
Supporting Information
Figure S1 Viability of SH-SY5Y cells treated with a-synuclein
amyloids and measured by using WST-1 assay. Percentage of
viable treated cells compared to untreated cells is shown in y-axis
and the samples added to cells are indicated along x-axis. Cell
viability was measured after 24 h (blue bars) and 48 h (red bars) of
co-incubation with amyloids, respectively. ***P,0.0001.
(TIF)
Figure S2 SDS-PAGE of freshly dissolved a-synuclein. Refer-
ence molecular makers are shown in lane 1 and freshly dissolved
a-synuclein with molecular mass of ca. 16 kDa – in lane 2.
(TIF)
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